THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRIMATI SUSHILA ROHATGI): (a) and (b) Implementation of the proposed Bakreshwar Thermal Power Project could be taken up after the availability of funds required for the purpose has been tied up and investment approval has been accorded.

(c) and (d) Offers have been received, including from a Consortium led by M|s. Technopromexport (USSR) for turn-key implementation of the proposed Project. A view in this regard could be taken after the offers have been duly assessed and the project has received investment approval.

Category I and II bulk drugs

1522. DR. RATNAKAR PANDEY: Will the the Minister of INDUSTRY be pleased to state:

(a) what is the installed and licensed capacity of each of Category I and II bulk drugs;

(b) what is the estimated requirement of 1986-87 of each drug;

(c) what is the total production of each of these drugs during the last three years; and

(d) what is the percentage increase or decrease in each case?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R K. JAICHANDRA SINGH): (a) Licenced capacities of Category I and II bulk drugs to the extent monitored by my Ministry, are published in the Performance Budget of this Ministry, copies of which have been placed on the Table of the House. Details of installed capacity are not available.

(b) Demand estimates for the period 1986-87 in respect of these drugs, to the extent monitored, are published in the 'Report of the Working Group on Drugs & Pharmaceuticals for the Seventh Five Year Plan', copies of which are available in Parliament Library.

(c) and (d) Details of production during the last three years, of these bulk drugs, to the extent monitored, are pubblished in the Performance Budget of this Ministry, copies of which are available in the Parliament Library.

Production of essential drugs by multinationals

1523. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the multinationals are not producing essential drugs such as Anti-T.B., Anti-Leprosy and Anti-Malaria;

(b) the names of the combinations which the multinationals are licensed to produce alongwith the licensed capacity of each drug of each company; and

(c) the production of these drugs by each of these companies during the last three years?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) No, Sir. Among the FERA companies M|s. Pfizer Ltd. produces two anti-T.B. drugs i.e. PAS and its salts and Isoniazid and M|s. Bayer Ltd. produces an anti-malarial drugs that is Chloroquin.

(b) and (c) To the extent information is available. only M|s. Pfizer Ltd. produces combinations of these drugs which are as follows:

(i) ISOZONE (Tabs.) containing Isoniazid and Thiacetazone

(ii) SOZONE FORTE (Tabs.) containing Isoniazid and Thiacetazone.

(iii) PASONEX-S (granules) containing Sodium Aminosalicylate and Isoniazid.

However, licenced capacity for formulations are only given in terms of percentage of bulk drugs which the company is eligible to formulate as per the Drug Policy. In case of FERA companies this is 50 per cent. The details of licenced capacity and production of these drugs are given below:

Name of the item/ Name of the Company	Licenced Capacity	Production 1983-84	1984-85	1985-86
	MT			
PAS & Its Salts M/s. Pfizer Ltd.	110	3.67	8.52	..
ISONIAZID M/s. Pfizer Ltd.	80	56.56	80.01	71.74
CHLOROQUIN M/s. Bayer Ltd.	12	34.79	35.48	36.06

Price approval drug companies

1524. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that a number of companies have not obtained price approvals after crossing the limit of annual sales turnover of Rs. 50 lakhs;

(b) whether his Ministry has isssued notices to certain companies to obtain the price approvals;

(c) the names of the companies to which notices have been issued recently;

(d) how many companies obtained price approval of their products being marketed by them;

(e) whether most of the companies either did not obtain any price approval or obtained price approval for only few products; and

(f) if so, what are the details regarding the names of the companies and action taken against them?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R K. JAICHANDRA SINGH): (a) to (c) Names of the companies who were issued notices to obtain price approval for their products after crossing the limit of Rs. 50 lakhs per annum in sales turnover, are given in the attached statement (*See* below).

(d) to (f) Most of these units have either obtained the price approval for their products or have submitted their applications for that purpose.

Statement

1. M|s. Concept Pharmaceuticals
2. M|s. Lord's Pharmaceuticals
3. M|s. Gratus Pharma
4. M|s. Glemark Pharmaceuticals Pvt. Ltd.
5. M|s. Martin Pharmaceuticals
6. M|s. Sidmark Labs. (I) Pvt. Ltd.
7. M|s. Julabs
8. M|s. Mexin Medicament (P) Ltd.
9. M|s. Dyanamic Pharmaceuticals Pvt. Ltd.,
10. M|s. Comteek Labs.
11. M|s. Calfax Labs. (P) Ltd.
12. M|s. Martidale Pharmaceuticals
13. Novocem Abs. Pvt. Ltd.
14 M|s. SOL Pharmaceuticals Ltd.
15. Pfimex International
16. M|s. Imkenex India Ltd.
17. M|s. Bio Vaccines Pvt. Ltd.
18. M|s. Citadel Fine Pharmaceuticals (P) Ltd.
19. M|s. Indochem Labs. Pvt. Ltd.
20. M|s. Sunways (I) Ltd.
21. M|s. Associated Labs. (P) Ltd.